PLoS ONE (Jan 2021)

Intensity of de novo DSA detected by Immucor Lifecodes assay and C3d fixing antibodies are not predictive of subclinical ABMR after Kidney Transplantation.

  • Dominique Bertrand,
  • Rangolie Kaveri,
  • Charlotte Laurent,
  • Philippe Gatault,
  • Maïté Jauréguy,
  • Cyril Garrouste,
  • Johnny Sayegh,
  • Nicolas Bouvier,
  • Sophie Caillard,
  • Luca Lanfranco,
  • Antoine Thierry,
  • Arnaud François,
  • Françoise Hau,
  • Isabelle Etienne,
  • Dominique Guerrot,
  • Fabienne Farce

DOI
https://doi.org/10.1371/journal.pone.0249934
Journal volume & issue
Vol. 16, no. 4
p. e0249934

Abstract

Read online

De novo donor-specific antibodies (dnDSA) are associated with antibody-mediated rejection (ABMR) and allograft loss. We tested Immucor* (IM) Luminex Single-antigen beads (LSAB) assay and C3d-fixing antibodies in the setting of dnDSA and subclinical (s) ABMR. This retrospective multicentric study included 123 patients biopsied because of the presence of subclinical de novo DSA detected by One Lamda* Labscreen (MFI > 1000). In 112 patients, sera of the day of the biopsy were available and tested in a central lab with IM Lifecodes LSAB and C3d fixing antibodies assays. In 16 patients (14.3%), no DSA was detected using Immucor test. In 96 patients, at least one DSA was determined with IM. Systematic biopsies showed active sABMR in 30 patients (31.2%), chronic active sABMR in 17 patients (17.7%) and no lesions of sABMR in 49 KT recipients (51%). Intensitity criteria (BCM, BCR and AD-BCR) of DSA were not statistically different between these 3 histological groups. The proportion of patients with C3d-fixing DSA was not statistically different between the 3 groups and did not offer any prognostic value regarding graft survival. Performing biopsy for dnDSA could not be guided by the intensity criteria of IM LSAB assay. C3d-fixing DSA do not offer added value.